Rights issue in Vicore oversubscribed by 33 percent – The company receives SEK 82.4M

2018-10-09 | Regulatory

Mölndal, October 9, 2018 – Vicore Pharma Holding AB (publ) (”Vicore” or the ”Company”) has completed the new share issue with pre-emption rights for existing shareholders resolved by the Extraordinary General Meeting on 13 August, 2018 (the “Rights Issue”). The subscription period ended on 3 October, 2018 and the outcome confirms that 8,193,643 shares were subscribed for using subscription rights, corresponding to approximately 99.4 percent of the Rights Issue. In addition, applications for subscription without subscription rights of 2,770,796 shares have been received, corresponding to approximately 33.6 percent of the Rights Issue. Thus, the Rights Issue is oversubscribed by 33 percent. The Company will receive SEK 82.4M before issue costs through the Rights Issue.

Comment from Carl-Johan Dalsgaard, CEO

”It is gratifying that we have now completed the rights issue and therefore can fully focus on the clinical development plan, where we are currently working on the design of the forthcoming Phase II study for C21. The positive outcome in the rights issue is a clear indication that there is strong support for our strategy with our shareholders, which we will manage in the best possible way through the continued development of our two projects, VP01 and VP02.”

Subscription and allotment

Those registered as shareholders in Vicore on the record date on 17 September 2018 had pre-emption rights to subscribe for new shares in the Company. For each existing share one (1) subscription right was received. Three (3) subscription rights entitled to subscription of one (1) new share to a subscription price of SEK 10.00. In addition, the opportunity to apply for subscription of shares without the use of subscription rights was offered. Prior to the Rights Issue, a number of existing shareholders declared their intention to subscribe or entered subscription commitment agreements with the Company totaling to approximately SEK 57.7M, corresponding to 70 percent of the Rights Issue.

Allotment of shares has been made in accordance with the principles set out in the prospectus published by the Company on 18 September, 2018. Notice of allotment of shares subscribed for without the use of subscription rights is expected to be distributed on 9 October, 2018. The subscribed and allotted shares shall be paid in cash no later than on the settlement day, 11 October, 2018, in accordance with instructions on the contract note. Nominee shareholders will receive a notice of allotment of shares in accordance with each nominee’s internal routines. Only those who are allotted shares will be notified.

Number of shares and share capital

The Company’s share capital will increase by SEK 4,120,000.96 SEK to a total of SEK 16,480,003.84 after registration of the Rights Issue with the Swedish Companies Registration Office (Sw. Bolagsverket). The number of shares in the Company will increase by 8,240,002 shares to a total of 32,960,008 shares. Shareholders who did not participate in the Rights Issue will be diluted by 25 percent of the total share capital and votes in the Company.

Trading in paid subscription shares (Sw. betalda tecknade aktier)

Trading in paid subscription shares (BTA) will take place on Nasdaq First North until the Rights Issue has been registered by the Company with the Swedish Companies Registration Office. The registration is expected to be completed around 26 October, 2018.

Advisors

Erik Penser Bank AB is the financial advisor and MAQS Advokatbyrå is the legal advisor to Vicore in connection with the Rights Issue.

For further information, please contact:

Dr. Carl-Johan Dalsgaard, CEO: +46 709 759 863, carl-johan.dalsgaard@vicorepharma.com 

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08:00 CET on October 9, 2018.

Vicorepharma

On vicorepharma.com, we use so-called cookies to analyze how our website is used in order to optimize and improve it. You choose yourself whether you want to consent to our use of cookies.

Vicorepharma is responsible for placing cookies on the website and for the processing of your personal data collected by them. For more information about our processing of your personal data, see our privacy policy

Cookie policy

Your consent applies to the following domain: vicorepharma.com
The cookie policy was last updated: 2023-06-29

Privacy Policy

Show the cookies used on our website

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

 

What are cookies?

A cookie is a small text file that is placed on your device (computer/mobile/tablet that has access to the internet) by the website you visit – if you give your consent to this. The cookie can, for example, recognize you as a user when you visit our website and make it possible to remember important information that makes your visit more comfortable and provides an improved user experience. Cookies are so-called passive files that cannot spread dangerous software or viruses on your mobile device or computer.

There are two types of cookies, permanent cookies and session cookies. At vicorepharma.com we use both permanent cookies and session cookies. Permanent cookies are saved as a file on the computer for a certain time until the server that placed them, or you as a visitor choose to delete them. Session cookies are temporarily stored when you as a visitor are on the website and disappear when you close your browser.

Cookies can also be divided into first-party cookies and third-party cookies. First-party cookies are placed by the website you are visiting, while third-party cookies are placed by another website. At vicorepharma.com, we use both first-party cookies and third-party cookies.

 

How to avoid cookies

When you visit our website, you can refuse all or certain types of cookies. You can also withdraw or change your consent at any time by clicking here.

You can also block cookies by changing the settings in your browser. Then your browser will automatically refuse cookies or inform you when a website requests to store cookies.

After your visit, you can review and delete the permanent cookies that have been stored in your browser. In the list below, you will see the name of the cookies vicorepharma.com saves so that you can easily identify them.

Here you will find more information about how to manage cookies in your browser:

 

Cookies used by third parties

On vicorepharma.com there may be content that is embedded from YouTube. YouTube places cookies in your browser when you visit youtube.com or when you click on embedded content from YouTube on our website. vicorepharma cannot control these cookies or the personal data and information that may be collected. vicorepharma does not use the targeted marketing services offered by YouTube. As a user, you therefore need to check YouTube’s website for further information on how they manage cookies, what information they collect and how you can delete any third-party cookies.

 

Cookies used on vicorepharma.com

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

General

Vicore Pharma Holding AB (“Vicore”) shall only process personal data in accordance with applicable data protection law and high industry standards.

 

Personal data.

Vicore processes personal data provided to us;
(i) by you in the day-to-day communications, or

(ii) in connection with entering into or performing an agreement or business arrangement with you, or
(iii) by a third party allowed by law or your consent.

The personal data may consist of contact and identification details and other information relevant to the situation.

 

Purpose.

Vicore process personal data for the purpose of communicating with you and to perform, manage and comply with agreements between us as well as rights and obligations which are allowed by law or applicable regulation.

 

Legal grounds.

The legal grounds for processing personal data is either;
(i) your consent which shall be considered provided when you either voluntary submit the personal data or enter into an agreement with us, or
(ii) a legitimate interest allowed under law.

 

Security

Vicore shall use adequate technical and organisational security measures to protect the personal data from loss and to safeguard against access from unauthorised persons.

Transfers of personal data may only occur;
(i) to third parties who perform services on Vicore behalf and who may only process personal data in accordance with our instructions, and may not use personal data for their own purposes; and
(ii) outside the EU/EEA only in accordance with applicable data protection laws and subject to the EU Commission’s standard contractual clauses, and
(iii) as otherwise permitted by law or your consent.

Duration.

The duration we process personal data is limited to what is reasonable for the purpose of the processing, unless otherwise required or permitted by law.

 

Rights

Vicore is the controller of the personal data processing, meaning that we are responsible for that the personal data is processed correctly and in accordance with applicable data protection laws.

Unless prevented by applicable law, regulation or agreement data subjects have the right to;
(i) know what personal data we process about them,
(ii) request that we rectify or erase inaccurate or incomplete personal data
(iii) object to specific processing of personal data, and
(iv) receive the personal data provided by them and have the personal data transferred to another party responsible for data processing.

All communications with Vicore regarding how we process personal data or exercise of any of your rights can be sent by e-mail to info@vicorepharma.com or by post to the address above.

Reports and complaints can also be directed to Datainspektionen who is the supervisory authority for our processing of personal data.